HER2 education for advanced practice providers (APPs)
About the program
Advances in biomarker testing and the introduction of HER2‑targeted therapies are transforming care for patients with NSCLC. As precision medicine expands, nurse practitioners and advanced practice providers play an essential role in helping patients navigate testing, understand results, and manage increasingly complex treatment pathways.
HER2 mutations are an important biomarker in NSCLC, with new therapies and updated guidance shaping how care is delivered.
This expert‑led program supports oncology nurses and APPs in delivering high‑quality, individualized care by providing practical education on HER2 biomarker testing, current evidence‑based treatment recommendations, and approaches to managing treatment‑related toxicities.
Learning objectives
Following completion of this independent educational program, you will be able to:
- Support multidisciplinary teams by applying current evidence on biomarker testing and HER2-targeted therapies to real-world patient care
- Integrate communication and interpretation skills to effectively convey HER2 biomarker results to patients and multidisciplinary teams
- Implement evidence-based approaches for managing treatment-related toxicities in patients with HER2 mutation-positive NSCLC
Faculty
Beth Sandy (Program Director)
Thoracic Oncology Nurse Practitioner, University of Pennsylvania
Read more
Beth Sandy is a nurse practitioner in thoracic medical oncology at the University of Pennsylvania in Philadelphia, US. She has been in this role for over 20 years. She also speaks and publishes frequently on topics related to the care of patients with lung cancer. She is also on editorial boards and several committees pertaining to nursing and lung cancer.
Disclosures:
Consultative services for: Abbvie, Boehringer Ingelheim, Nuvation Bio, Pfizer
Speaker bureau: Amgen, AstraZeneca, Janssen, Jazz, Lilly, Merck
Nicolas Girard
Professor of Respiratory Medicine, Versailles Saint Quentin University, Paris Saclay, Paris, France
Read more
Nicolas Girard is a pneumologist specializing in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. He is domain leader for rare thoracic cancers for the European Reference Network EURACAN. Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. He is also the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Department at Institut Curie in Paris. Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.
Disclosures:
Research grants/support from: Abbvie, Amgen, AstraZeneca, Beigene, Boeringer Ingelheim, Bristol Myers Squib, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan.
Consultative services for: Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Sivan Takeda.
Participation on a data safety monitoring board for Hoffmann-La Roche.
Employment of a family member with AstraZeneca.
Target audience
Advanced practice providers such as nurse practitioners and physician assistants within the oncology.
Accreditation
This continuing education activity has been approved by the International Council of Nurses (ICN) for the award of 0.5 International Continuing Nursing Education Credits (ICNECs) upon successful completion of the accredited course.
Interactive case studies
For CME-accredited activities, look for the badge
Navigating HER2 biomarker testing with confidence
Video-based case study covering how to identify HER2 mutations, interpret biomarker test reports and communicate findings to patients with Beth Sandy
HER2-targeted therapy in practice
Video-based case study exploring best practices for management of HER2 mutation-positive NSCLC, including how to support patients on HER2-targeted therapies, with Nicolas Girard
Interactive resources
Interactive report reader
Practice interpreting example biomarker test results for a patient with HER2 mutation-positive NSCLC with Beth Sandy and Nicolas Girard
HER2 adverse event navigator
Clinical guide providing practical guidance on recognizing, managing, and preventing adverse events associated with HER2-targeted therapies